ArticleFrontiers in cellular and infection microbiology2025
Chitosan-silver nanocomposites: promising alternatives for combating azole-resistant
Article in Frontiers in cellular and infection microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The emergence of azole-resistant strains of Objectives: This study aimed to evaluate the synthesis, characterization, antifungal properties, and low toxicity in an invertebrate model of Chi-AgNPs compared with those of chitosan and silver nanoparticles (AgNPs) alone, particularly against azole-resistant Methods: Chi-AgNPs were synthesized via a chemical reduction method and characterized using particle size analysis, ultraviolet-visible (UV-Vis) spectroscopy, Fourier transform infrared (FTIR), scanning electron microscopy (SEM), and transmission electron microscopy (TEM). Antifungal efficacy was assessed through minimum inhibitory concentration (MIC), minimum fungicidal concentration (MFC), microbial growth curves, and Results: Compared with chitosan and AgNPs alone, Chi-AgNPs exhibited superior physicochemical properties, with smaller and more uniform particle sizes (average: 212.5 nm) and improved dispersion stability based on immediate characterization data. The MIC and MFC of Chi-AgNPs (8-16 μg/mL and 128 μg/mL, respectively) were significantly lower than those of chitosan and AgNPs (128 μg/mL and >256 μg/mL, respectively). Compared with AgNPs, Chi-AgNPs induced higher ROS levels ( Conclusions: This study highlights the potential of Chi-AgNPs as promising alternatives to combat azole-resistant fungal infections. These findings provide a foundation for further development of Chi-AgNPs as novel antifungal agents with broad applicability.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.